Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

134.56 +0.07 (+0.05%)
Streaming Delayed Price Updated: 12:40 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apogee Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
This Stock Keeps Raising Its Dividend No Matter What the Market Does -- and Wall Street Thinks It's a Buy Right Now ↗
There is no end in sight for the drugmaker's dividend growth streak. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Should You Buy AbbVie Stock Hand Over Fist Before July 31? ↗
The recent rally could pave the way for "sell the news" volatility, but don't let this scare you out of a long-term position. 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Why Wall Street Can't Get Enough of This Dividend King ↗
AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Reasons to Buy AbbVie Stock Like There's No Tomorrow ↗
It looks like a great buy-and-hold option. 
Via The Motley Fool
Topics Intellectual Property
News headline image
How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend? ↗
There's no need to panic. 
Via The Motley Fool
News headline image
My 2 Favorite Dividend Kings to Buy Right Now ↗
They can help stabilize your portfolio in these otherwise volatile times. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Halper Sadeh LLC is Investigating Whether NEE, CRBG, RMAX, APGE are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
What This Apogee Insider Move Might Mean After a 247% Stock Run ↗
Henderson's disposition included a 20,000-share open-market sale and a 75,046-share charitable gift. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty ↗
AbbVie inherited its status as a Dividend King, but it is building a strong foundation to continue the dividend streak. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Dividend ETF Quietly Outperforming the S&P 500 ↗
This dividend ETF's focus beyond yield continues to pay off for investors. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Shareholder Alert: Ademi LLP investigates whether Apogee Therapeutics is obtaining a Fair Price for Public Shareholders
From Ademi LLP
Via GlobeNewswire
News headline image
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy? ↗
AbbVie knows how to plan ahead. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Halper Sadeh LLC is Investigating Whether APGE, LPRO, HUN, AVNS are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
News headline image
Why AbbVie Stock Jumped Today ↗
An intriguing acquisition could bring exciting new drugs into the medicine maker's development pipeline. 
Via The Motley Fool
News headline image
AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King? ↗
The company is already renowned by many as a giant in the segment. 
Via The Motley Fool
News headline image
Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer ↗
On June 22, 2026, Apogee Therapeutics shares surged as investors reacted to AbbVie's proposed acquisition terms. 
Via The Motley Fool
Topics Stocks
Top movers analysis one hour before the close of the markets on 2026-06-22: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)
From Brodsky & Smith LLC
Via GlobeNewswire
Which stocks are moving on Monday? ↗
Via Chartmill
Monday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
APGE Stock Alert: Halper Sadeh LLC is Investigating Whether Apogee Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
These stocks that are showing activity before the opening bell on Monday. ↗
Via Chartmill
News headline image
Apogee Therapeutics Maps Phase 3 Push for Zumilokibart, Backed by Blackstone Funding ↗
Apogee Therapeutics (NASDAQ:APGE) executives outlined plans to advance zumilokibart, the company’s IL-13-targeting antibody, into late-stage development for atopic dermatitis while expanding the... 
Via MarketBeat
Topics Initial Public Offering
News headline image
Apogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backing ↗
Apogee Therapeutics (NASDAQ:APGE) executives said the company is preparing to move its lead drug candidate, zumilokibart, into Phase 3 testing later this year after reporting Phase 2b data in atopic... 
Via MarketBeat
Topics Initial Public Offering
News headline image
Apogee Therapeutics to Participate in Upcoming June Conferences
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis
From Apogee Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.